États-Unis · Agences & temps réel · PR Newswire

Perlmutter Cancer Center Taps Vivek Subbiah, MD, to Lead Early-Phase Drug Development and Rare Cancer Programs

Publié par PR Newswire · États-Unis il y a 1 h

The physician-scientist helped advance landmark tumor-agnostic therapies that target cancer's genetic drivers. NEW YORK, Oct. 22, 2026 /PRNewswire/ -- NYU Langone Health today…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

Perlmutter Cancer Center Taps Vivek Subbiah, MD, to Lead Early-Phase Drug Development and Rare Cancer Programs

À lire aussi

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Lyric Releases Framework for Measuring Healthcare Decision Intelligence Maturity in Payment Accuracy

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

Perlmutter Cancer Center Taps Vivek Subbiah, MD, to Lead Early-Phase Drug Development and Rare Cancer Programs

Partager

À lire aussi

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Lyric Releases Framework for Measuring Healthcare Decision Intelligence Maturity in Payment Accuracy

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum